Pharmacotherapies for Alcohol and Substance Abuse Consortium   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Houston Texas United States (2010)

Organization Overview

First Clinical Trial
2018
NCT03548714
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pharmacotherapies for Alcohol and Substance Abuse Consortium

Active Ingredients

Drugs in Phase 2 Trials (4)

buprenorphine (1 trial)

lofexidine (lucemyra) (1 trial)

naltrexone (revia) (1 trial)

zonisamide (Zonegran) (1 trial)

Drugs in Phase 1 Trials (2)

dexmedetomidine (precedex) (1 trial)

PT150 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Disease (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 6